Topological Polar Surface Area, Molecular Weight, and Rotatable
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) United States Patent (10) Patent No.: US 6,767,552 B2 Narang (45) Date of Patent: Jul
USOO6767552B2 (12) United States Patent (10) Patent No.: US 6,767,552 B2 Narang (45) Date of Patent: Jul. 27, 2004 (54) ADHESIVE TREATMENT FOR ORAL 5.530,037 A 6/1996 McDonnell et al. FUNGAL INFECTION 5,554,365 A 9/1996 Byram et al. 5,575.997 A 11/1996 Leung et al. (75) Inventor: Upvan Narang, Raleigh, NC (US) 5,580,565 A 12/1996 Tighe et al. 5,582,834 A 12/1996 Leung et al. (73) Assignee: Closure Medical Corporation, 5,613,942 A 3/1997 Lucast et al. Raleigh, NC (US) 5,624,669 A 4/1997 Leung et al. 9, 5,653,769 A 8/1997 Barley, Jr. et al. 5,661,170 A 8/1997 Chodosh (*) Notice: Subject to any disclaimer, the term of this 5,665,817 A 810: E. al. patent is extended or adjusted under 35 5,684,042 A 11/1997 Greff et al. U.S.C. 154(b) by 359 days. 5,716,607 A 2/1998 Byram et al. 5,717.005 A 2/1998 Richardson (21) Appl. No.: 09/898,092 5,725,491 A 3/1998 Tipton et al. 5,730,994. A 3/1998 Askill et al. (22) Filed: Jul. 5, 2001 5,753,699 A 5/1998 Greff et al. 5,755,680 A 5/1998 Ghodsian (65) Prior Publication Data 5,762.919 A 6/1998 Greff et al. 5,762.955 A 6/1998 Smith US 2003/0007947 A1 Jan. 9, 2003 5,783,177 A 7/1998 Greff et al. -
Scanned Using Fujitsu 6670 Scanner and Scandall Pro Ver 1.7 Software
1816 1990/826 THE DRUG TARIFF 1990 PURSUANT to section 99 of the Social Security Act 1964, the Minister of Health hereby gives the following direction. ANALYSIS I. Title and commencement 15. Disputes 2. Interpretation PART I PART III GENERAL RULES AFFECTING DIRECTION MISCELLANEOUS PROVISIONS 3. Scope of direction 16. Claims on Department 4. Standards I 7. Allergy treatment sets 5. Charges for requirements 18. Payment for non·disposable syringes and needles PART 11 19. Payment for plastic syringes RULES FOR PRICING 20. Period and quantity of supply for 6. Calculation of payments doctors' and midwives' prescriptions 7. Application of Pricing Schedules 21. Period and quantity of supply for 8. Computation of selling price prescriptions for oral contraceptives 9. Rounding calculations 22. Period and quantity of supply for 10. Minimum charges dentist's prescriptions 11. Adjustment of dose volumes of oral 23. Original packs, and certain antibiotics liquid requirements 24. Bulk supply orders 12. Water 25. Practitioner's supply orders 13. Payment for bulk supply orders 26. Wholesale supply orders 14. Payment for practitioners' supply 27. Revocations and savings orders Schedule DIRECTION 1. Tide and commencement-(I) This direction may be cited as the Drug Tariff 1990. (2) This direction shall come into force on the 1st day of December 1990. 2. Interpretation-(1) In this direction, unless the context otherwise requires,- "The Act" means the Social Security Act 1964: "Board" means an Area Health Board under the Area Health Boards Act 1983 or a Hospital -
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0 -
US5116603.Pdf
||||||||||||||||||| US0051 16603A United States Patent (19) 11) Patent Number: 5,116,603 Friedman (45) Date of Patent: May 26, 1992 (54) ORAL ANTIFUNGAL PREVENTATIVE, AND 99.0957 5/1965 United Kingdom . METHOD OF USE OTHER PUBLICATIONS 75 Inventor: Michael Friedman, Jerusalem, Israel Friedman, "Plaque Inhibition by Sustained Release of 73) Assignee: Yissum Research Development Chlorhexide', J. Dental Res. Nov. 1985. Company of the Hebrew University of Soskolne, W. A. et al., "New Sustained Release Dosage Jerusalem, Jerusalem, Israel form of Chlorhexidine for Dental Use', J. Periodontal Res. 18:330-336, (1983). (21) Appl. No.: 465,786 Friedman, "New Sustained Release form of Chlorhexi 22 Filed: Jan. 18, 1990 dine for Denteal Use', J. Periodont Res. 17:323-328 (1982). Related U.S. Application Data Kostiala, I. et al., Acta Odontol. Scand. 37:87-101 (1979). Budtz-Jörgensen, E. et al., Community Dent. Oral 63 Continuation-in-part of Ser. No. 304,092, Jan. 31, 1989, Epidemiol. 3:115 (1975). abandoned. Odds, F. C., CRC Crit Rey. Microbiol. 15: 1-5 (1987). (51 int. Cl. ....................... A61K 6/00; A61K 31/74; Lehner, T. in Clin. Aspects of Immunol, P.G.H. Gell A61K 31/745; A61K 31/78 eds. et al., 3rd edition, Blackwell Scientific Public, Ox 52 U.S. Cl. ........................................ 424/53; 424/49; ford, 1975, pp. 1387-1427. 514/900; 514/902 Friedman, M. et al., IADR Prog. and Abstr. 59:905 58) Field of Search ....................... 424/78, 81, 83, 53, (1980), No. 72. 424/49; 514/900, 902,953 Friedman, M. et al., J. Dent. Res. 64:1319-1321 (1985). -
Anti-Fungal Agent Antimykotischer Wirkstoff Agent Antifongique
(19) TZZ _¥_T (11) EP 2 762 139 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4178 (2006.01) A61P 31/10 (2006.01) 13.04.2016 Bulletin 2016/15 C07D 409/06 (2006.01) (21) Application number: 12836654.9 (86) International application number: PCT/JP2012/074580 (22) Date of filing: 25.09.2012 (87) International publication number: WO 2013/047530 (04.04.2013 Gazette 2013/14) (54) ANTI-FUNGAL AGENT ANTIMYKOTISCHER WIRKSTOFF AGENT ANTIFONGIQUE (84) Designated Contracting States: (56) References cited: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • YASUKO NANJO ET AL.: ’In vitro Antifungal GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Activities of Clinically Available Topical PL PT RO RS SE SI SK SM TR Antifungal Drugs’ JAPANESE JOURNAL OF DERMATOLOGYvol. 117, no. 2, 20 February 2007, (30) Priority: 26.09.2011 JP 2011209903 pages 149 - 152, XP008173701 • NIWANO Y ET AL.: ’Efficacy of NND-502, a novel (43) Date of publication of application: imidazole antimycotic agent, in experimental 06.08.2014 Bulletin 2014/32 models of Candida albicans and Aspergillus fumigatus infections’ INTERNATIONAL (73) Proprietor: Nihon Nohyaku Co., Ltd. JOURNAL OF ANTIMICROBIAL AGENTS vol. 12, Tokyo 104-8386 (JP) no. 3, August 1999, pages 221 - 228, XP055104990 • SHIGERU ABE ET AL.: ’Anti-Candida Activities of (72) Inventors: Azole Antifungals in the Presence of Lysozyme • KOGA, Hiroyasu In Vitro’ JAPANESE JOURNAL OF MEDICAL Kawachinagano-shi MYCOLOGY vol. 39, no. -
Customs Tariff - Schedule
CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2018 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels. -
Review Article Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents
Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 204237, 13 pages http://dx.doi.org/10.1155/2013/204237 Review Article Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents Claudia Spampinato1,2 and Darío Leonardi3,4 1 Departamento de Qu´ımica Biologica,´ Facultad de Ciencias Bioqu´ımicas y Farmaceuticas,´ Universidad Nacional de Rosario (UNR), Suipacha 531, 2000 Rosario, Argentina 2 Centro de Estudios Fotosinteticos´ y Bioqu´ımicos (CEFOBI, UNR-CONICET), Suipacha 531, 2000 Rosario, Argentina 3 Departamento de Tecnolog´ıa Farmaceutica,´ Facultad de Ciencias Bioqu´ımicas y Farmaceuticas,´ Universidad Nacional de Rosario (UNR), Suipacha 531, 2000 Rosario, Argentina 4 Instituto de Qu´ımica Rosario (IQUIR, UNR-CONICET), Suipacha 531, 2000 Rosario, Argentina Correspondence should be addressed to Dar´ıo Leonardi; [email protected] Received 8 April 2013; Revised 6 June 2013; Accepted 6 June 2013 Academic Editor: Abdelwahab Omri Copyright © 2013 C. Spampinato and D. Leonardi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The genus Candida includes about 200 different species, but only a few species are human opportunistic pathogens and cause infections when the host becomes debilitated or immunocompromised. Candida infections can be superficial or invasive. Superficial infections often affect the skin or mucous membranes and can be treated successfully with topical antifungal drugs. However, invasive fungal infections are often life-threatening, probably due to inefficient diagnostic methods and inappropriate initial antifungal therapies. Here, we briefly review our current knowledge of pathogenic species of the genus Candida and yeast infection causes and then focus on current antifungal drugs and resistance mechanisms. -
Determination of Cost Effective Topical Therapy for Pityriasis Versicolor Fawad Muzaffar*, Amer Ejaz**, Khalid Mahmood†
Journal of Pakistan Association of Dermatologists 2008; 18: 159-164. Original Article Determination of cost effective topical therapy for pityriasis versicolor Fawad Muzaffar*, Amer Ejaz**, Khalid Mahmood† * Dermatology Department, Combined Military Hospital, Kohat Cantonment, Pakistan. ** Dermatology Department, Combined Military Hospital, Kharian Cantonment, Pakistan. † Dermatology Department, PAF Hospital Islamabad, Pakistan. Abstract Objective To compare the cost, efficacy and compliance between shampoo (2.5 % selenium sulphide), soap (3% salicylic acid-10% sulphur), and gel (2% ketoconazole) in the treatment of pityriasis versicolor. Patients and methods This comparative, randomized, single-blind clinical trial study was carried out at Combined Military Hospital Multan from May 2005 to September 2005. After randomization and assessment of inclusion criteria, patients with diagnosis of pityriasis versicolor were divided into three groups. Group I applied shampoo for 10 minutes daily for 1 week. Group II applied soap for 5 minutes daily for a period of 4 weeks. Group III applied gel for 5 minutes daily for 5 days. Cure was defined as negative skin scrapings for fungal hyphae at the end of treatment period. Cost of treatment was defined as cost of treatment for the group at baseline divided by the number of cured patients in each group at the end of treatment period. Efficacy was defined as the percentage of cure rate achieved at the end of treatment period. Compliance was defined as the number of patients completing treatment in each group. Patients were evaluated at presentation, at the end of treatment, and followed up at 4 weeks post treatment. Results 90 patients were enrolled, 63 patients completed the treatment period, and 44 patients completed the follow up period. -
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7 -